CC FY2025 SEC EDGAR DEF 14A #57 of 168 in industry

Chemours Co CEO pay ratio

The CEO earned $8.6M in FY2025 against median worker pay of $121,131 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-03-10
Industry
Chemicals & Pharmaceuticals
Industry rank
#57/168

Data updated August 2026

Subscribe to Chemours Co CEO pay filing updates (RSS)

CEO-to-worker pay ratio
71:1
Moderate (Scale: 0–1000:1)
CEO pay
$8.6M
Median worker
$121,131

Answer first

Chemours Co's FY2025 CEO total of $8.6M ranks #629 of 1,423 complete filings; its 71:1 pay ratio ranks #817. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $121,131. Industry placement uses the FY2025 SIC-28 peer cohort (# 57 of 168, 67th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#629
$8.6M of 1,423 FY2025
Ratio rank
#817
71:1 of 1,423
Industry pct
67th
above the industry median pay ratio

How Chemours Co ranks nationally

Chemours Co CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$8,600,301 Top 44% higher than 56% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Chemours Co vs. Chemicals & Pharmaceuticals peers

CEO total pay ($8.6M) against pay ratio (71:1) for Chemours Co (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both7015949.311875670.916735392.521595114.126454835.840.5:149.0:157.5:166.0:174.5:1CEO total payPay ratio (CEO : median worker)Chemours Co, CEO total pay: 8600301 · Pay ratio (CEO : median worker): 71:1Chemours CoJazz Pharmaceuticals plc, CEO total pay: 19418256 · Pay ratio (CEO : median worker): 69:1Jazz Pharmaceuticals plcXeris Biopharma Holdings, Inc., CEO total pay: 16937606 · Pay ratio (CEO : median worker): 73:1Xeris Biopharma Holdings, Inc.Tg Therapeutics, Inc., CEO total pay: 25571250 · Pay ratio (CEO : median worker): 67:1Tg Therapeutics, Inc.Niagen Bioscience, Inc., CEO total pay: 8381900 · Pay ratio (CEO : median worker): 67:1Niagen Bioscience, Inc.
Chemours Co vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Chemours Co's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Chemours Co

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
71:1
FY2025
vs prior FY
+13:1
from FY2024 58:1
CEO $ YoY
+30%
$8.6M latest
Filings shown
5
FY2021–2025
Chemours Co CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $5.6M - $109,148 51:1 -
2022 $7.7M +38% $108,156 71:1 +20:1
2023 $7.3M -4.5% $109,473 67:1 -4:1
2024 $6.6M -10% $113,856 58:1 -9:1
2025 $8.6M +30% $121,131 71:1 +13:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1627223, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
71:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$8.6M
Companies in Industry
168
vs. Industry Median
Above
#57 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Chemours Co: MODEST · HEAVY pay ratio

Chemours Co's FY2025 ratio 71:1 ranks #57 of 168 Chemicals & Pharmaceuticals filers (67th percentile). the CEO earned 71× the median employee ($121,131) in FY2025.

Median employee $121,131 (ELITE-MED); MODEST · HEAVY stamps put about 71 median-wage years per CEO year.

CEO Total Pay

$8.6M

FY2025 Summary Compensation, near median

Pay Ratio

71:1

Near industry median

Chemours Co in the higher Chemicals & Pharmaceuticals third

Chemours Co's FY2025 ratio 71:1 ranks #57 of 168 Chemicals & Pharmaceuticals filers (67th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Chemours Co's $8.6M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #629 and ratio rank #817 split - treat 71:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$8.6M
Median Employee Pay
$121,131
Pay Ratio
71:1
Filing Date
2026-03-10

Company Info

Ticker
CC
CIK
1627223
Industry
Chemicals & Pharmaceuticals
SIC Code
2800
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1627223, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Chemours Co's FY2025 ratio 71:1 ranks #57 of 168 Chemicals & Pharmaceuticals filers (67th percentile).

Read with Chemours Co

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Kymera Therapeutics, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.6M (Δ $1K heavier vs Chemours Co); FLOOR · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Alphatec Holdings, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.6M (Δ $6K heavier vs Chemours Co); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Stanley Black & Decker, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.6M (Δ $21K lighter vs Chemours Co); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Cerence Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.6M (Δ $23K lighter vs Chemours Co); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Jazz Pharmaceuticals plc (SIC 28 pole)

Jazz Pharmaceuticals plc stamps MODEST · PEAK nearest in-SIC by ABS(pay_ratio) to Chemours Co's MODEST filing.
National dual ranks · #629/#817

Chemours Co's FY2025 package sits #629 by CEO dollars and #817 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Chemours Co's MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Chemours Co (CIK 1627223), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.